ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Malignant Mesothelioma Therapeutic Market Research Report 2026
Published Date: 2026-02-25
|
Report Code: QYRE-Auto-13B13087
Home | Market Reports | Health| Health Conditions| Cancer
Global Malignant Mesothelioma Therapeutic Market Research Report 2023
BUY CHAPTERS

Global Malignant Mesothelioma Therapeutic Market Research Report 2026

Code: QYRE-Auto-13B13087
Report
2026-02-25
Pages:125
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Eli Lilly
TEVA
Sanofi
Bristol–Myers Squibb
Pfizer Inc
Roche
Merck
Ono Pharmaceutical
Mylan NV
Fresenius Kabi
Sun Pharmaceuticals
Eagle Pharmaceuticals
Qilu Pharma
Sichuan Huiyu Pharma
Nippon Kayaku
Amgen Inc
Jiangsu Haosen

Malignant Mesothelioma Therapeutic Market Size

The global Malignant Mesothelioma Therapeutic market was valued at US$ 401 million in 2025 and is anticipated to reach US$ 640 million by 2032, at a CAGR of 7.0% from 2026 to 2032.

Malignant Mesothelioma Therapeutic Market

Malignant Mesothelioma Therapeutic Market

Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium). Malignant mesothelioma is a cancer of the thin tissue (mesothelium) that lines the lung, chest wall, and abdomen. The major risk factor for mesothelioma is asbestos exposure.
The malignant mesothelioma therapeutics market is primarily driven by increasing asbestos exposure cases in developing nations and rising disease awareness among occupational workers. Significant advancements in immunotherapy and targeted therapies, particularly immune checkpoint inhibitors and VEGF inhibitors, are revolutionizing treatment outcomes. The FDA's accelerated approval pathway for orphan drugs and growing R&D investments in rare cancer treatments are further propelling market growth. Additionally, improved diagnostic techniques enabling earlier detection and a surge in biomarker-driven personalized medicine approaches are creating new therapeutic opportunities.
The market faces substantial hurdles including late-stage diagnosis in most patients, severely limiting treatment efficacy. High development costs for novel therapies and limited patient pools due to mesothelioma's rarity create commercial viability concerns for pharmaceutical companies. Stringent asbestos regulations in developed countries are reducing incident rates, paradoxically shrinking the addressable market. Furthermore, the lack of standardized treatment protocols and frequent chemotherapy resistance present significant clinical management challenges, while reimbursement issues for expensive emerging therapies restrict patient access in many healthcare systems.
This report delivers a comprehensive overview of the global Malignant Mesothelioma Therapeutic market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Malignant Mesothelioma Therapeutic. The Malignant Mesothelioma Therapeutic market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Malignant Mesothelioma Therapeutic market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Malignant Mesothelioma Therapeutic manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Malignant Mesothelioma Therapeutic Market Report

Report Metric Details
Report Name Malignant Mesothelioma Therapeutic Market
Accounted market size in 2025 US$ 401 million
Forecasted market size in 2032 US$ 640 million
CAGR 7.0%
Base Year 2025
Forecasted years 2026 - 2032
Segment by Type
  • Pemetrexed
  • Cisplatin
  • Immunotherapy Agents
  • Others
Segment by Application
  • Pleural Mesothelioma
  • Peritoneal Mesothelioma
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Eli Lilly, Teva, Sanofi, Bristol-Myers Squibb, Pfizer, Roche, Merck, Ono Pharmaceutical, Mylan, Fresenius Kabi, Sun Pharmaceuticals, Eagle Pharmaceuticals, Qilu Pharma, Sichuan Huiyu Pharma, Nippon Kayaku, Jiangsu Haosen, Amgen
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
  • Chapter 3: Provides a detailed view of the competitive landscape for Malignant Mesothelioma Therapeutic companies, covering revenue share, development plans, and mergers and acquisitions.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
  • Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
  • Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
  • Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
  • Chapter 12: Key findings and conclusions of the report.

FAQ for this report

How fast is Malignant Mesothelioma Therapeutic Market growing?

Ans: The Malignant Mesothelioma Therapeutic Market witnessing a CAGR of 7.0% during the forecast period 2026-2032.

What is the Malignant Mesothelioma Therapeutic Market size in 2032?

Ans: The Malignant Mesothelioma Therapeutic Market size in 2032 will be US$ 640 million.

Who are the main players in the Malignant Mesothelioma Therapeutic Market report?

Ans: The main players in the Malignant Mesothelioma Therapeutic Market are Eli Lilly, Teva, Sanofi, Bristol-Myers Squibb, Pfizer, Roche, Merck, Ono Pharmaceutical, Mylan, Fresenius Kabi, Sun Pharmaceuticals, Eagle Pharmaceuticals, Qilu Pharma, Sichuan Huiyu Pharma, Nippon Kayaku, Jiangsu Haosen, Amgen

What are the Application segmentation covered in the Malignant Mesothelioma Therapeutic Market report?

Ans: The Applications covered in the Malignant Mesothelioma Therapeutic Market report are Pleural Mesothelioma, Peritoneal Mesothelioma, Others

What are the Type segmentation covered in the Malignant Mesothelioma Therapeutic Market report?

Ans: The Types covered in the Malignant Mesothelioma Therapeutic Market report are Pemetrexed, Cisplatin, Immunotherapy Agents, Others

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Malignant Mesothelioma Therapeutic Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Pemetrexed
1.2.3 Cisplatin
1.2.4 Immunotherapy Agents
1.2.5 Others
1.3 Market by Application
1.3.1 Global Malignant Mesothelioma Therapeutic Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Pleural Mesothelioma
1.3.3 Peritoneal Mesothelioma
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Malignant Mesothelioma Therapeutic Market Perspective (2021–2032)
2.2 Global Malignant Mesothelioma Therapeutic Growth Trends by Region
2.2.1 Global Malignant Mesothelioma Therapeutic Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Malignant Mesothelioma Therapeutic Historic Market Size by Region (2021–2026)
2.2.3 Malignant Mesothelioma Therapeutic Forecasted Market Size by Region (2027–2032)
2.3 Malignant Mesothelioma Therapeutic Market Dynamics
2.3.1 Malignant Mesothelioma Therapeutic Industry Trends
2.3.2 Malignant Mesothelioma Therapeutic Market Drivers
2.3.3 Malignant Mesothelioma Therapeutic Market Challenges
2.3.4 Malignant Mesothelioma Therapeutic Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Malignant Mesothelioma Therapeutic Players by Revenue
3.1.1 Global Top Malignant Mesothelioma Therapeutic Players by Revenue (2021–2026)
3.1.2 Global Malignant Mesothelioma Therapeutic Revenue Market Share by Players (2021–2026)
3.2 Global Top Malignant Mesothelioma Therapeutic Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Malignant Mesothelioma Therapeutic Revenue
3.4 Global Malignant Mesothelioma Therapeutic Market Concentration Ratio
3.4.1 Global Malignant Mesothelioma Therapeutic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Malignant Mesothelioma Therapeutic Revenue in 2025
3.5 Global Key Players of Malignant Mesothelioma Therapeutic Head Offices and Areas Served
3.6 Global Key Players of Malignant Mesothelioma Therapeutic, Products and Applications
3.7 Global Key Players of Malignant Mesothelioma Therapeutic, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Malignant Mesothelioma Therapeutic Breakdown Data by Type
4.1 Global Malignant Mesothelioma Therapeutic Historic Market Size by Type (2021–2026)
4.2 Global Malignant Mesothelioma Therapeutic Forecasted Market Size by Type (2027–2032)
5 Malignant Mesothelioma Therapeutic Breakdown Data by Application
5.1 Global Malignant Mesothelioma Therapeutic Historic Market Size by Application (2021–2026)
5.2 Global Malignant Mesothelioma Therapeutic Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Malignant Mesothelioma Therapeutic Market Size (2021–2032)
6.2 North America Malignant Mesothelioma Therapeutic Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Malignant Mesothelioma Therapeutic Market Size by Country (2021–2026)
6.4 North America Malignant Mesothelioma Therapeutic Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Malignant Mesothelioma Therapeutic Market Size (2021–2032)
7.2 Europe Malignant Mesothelioma Therapeutic Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Malignant Mesothelioma Therapeutic Market Size by Country (2021–2026)
7.4 Europe Malignant Mesothelioma Therapeutic Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Malignant Mesothelioma Therapeutic Market Size (2021–2032)
8.2 Asia-Pacific Malignant Mesothelioma Therapeutic Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Malignant Mesothelioma Therapeutic Market Size by Region (2021–2026)
8.4 Asia-Pacific Malignant Mesothelioma Therapeutic Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Malignant Mesothelioma Therapeutic Market Size (2021–2032)
9.2 Latin America Malignant Mesothelioma Therapeutic Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Malignant Mesothelioma Therapeutic Market Size by Country (2021–2026)
9.4 Latin America Malignant Mesothelioma Therapeutic Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Malignant Mesothelioma Therapeutic Market Size (2021–2032)
10.2 Middle East & Africa Malignant Mesothelioma Therapeutic Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Malignant Mesothelioma Therapeutic Market Size by Country (2021–2026)
10.4 Middle East & Africa Malignant Mesothelioma Therapeutic Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Eli Lilly
11.1.1 Eli Lilly Company Details
11.1.2 Eli Lilly Business Overview
11.1.3 Eli Lilly Malignant Mesothelioma Therapeutic Introduction
11.1.4 Eli Lilly Revenue in Malignant Mesothelioma Therapeutic Business (2021–2026)
11.1.5 Eli Lilly Recent Development
11.2 Teva
11.2.1 Teva Company Details
11.2.2 Teva Business Overview
11.2.3 Teva Malignant Mesothelioma Therapeutic Introduction
11.2.4 Teva Revenue in Malignant Mesothelioma Therapeutic Business (2021–2026)
11.2.5 Teva Recent Development
11.3 Sanofi
11.3.1 Sanofi Company Details
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Malignant Mesothelioma Therapeutic Introduction
11.3.4 Sanofi Revenue in Malignant Mesothelioma Therapeutic Business (2021–2026)
11.3.5 Sanofi Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Details
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Malignant Mesothelioma Therapeutic Introduction
11.4.4 Bristol-Myers Squibb Revenue in Malignant Mesothelioma Therapeutic Business (2021–2026)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Malignant Mesothelioma Therapeutic Introduction
11.5.4 Pfizer Revenue in Malignant Mesothelioma Therapeutic Business (2021–2026)
11.5.5 Pfizer Recent Development
11.6 Roche
11.6.1 Roche Company Details
11.6.2 Roche Business Overview
11.6.3 Roche Malignant Mesothelioma Therapeutic Introduction
11.6.4 Roche Revenue in Malignant Mesothelioma Therapeutic Business (2021–2026)
11.6.5 Roche Recent Development
11.7 Merck
11.7.1 Merck Company Details
11.7.2 Merck Business Overview
11.7.3 Merck Malignant Mesothelioma Therapeutic Introduction
11.7.4 Merck Revenue in Malignant Mesothelioma Therapeutic Business (2021–2026)
11.7.5 Merck Recent Development
11.8 Ono Pharmaceutical
11.8.1 Ono Pharmaceutical Company Details
11.8.2 Ono Pharmaceutical Business Overview
11.8.3 Ono Pharmaceutical Malignant Mesothelioma Therapeutic Introduction
11.8.4 Ono Pharmaceutical Revenue in Malignant Mesothelioma Therapeutic Business (2021–2026)
11.8.5 Ono Pharmaceutical Recent Development
11.9 Mylan
11.9.1 Mylan Company Details
11.9.2 Mylan Business Overview
11.9.3 Mylan Malignant Mesothelioma Therapeutic Introduction
11.9.4 Mylan Revenue in Malignant Mesothelioma Therapeutic Business (2021–2026)
11.9.5 Mylan Recent Development
11.10 Fresenius Kabi
11.10.1 Fresenius Kabi Company Details
11.10.2 Fresenius Kabi Business Overview
11.10.3 Fresenius Kabi Malignant Mesothelioma Therapeutic Introduction
11.10.4 Fresenius Kabi Revenue in Malignant Mesothelioma Therapeutic Business (2021–2026)
11.10.5 Fresenius Kabi Recent Development
11.11 Sun Pharmaceuticals
11.11.1 Sun Pharmaceuticals Company Details
11.11.2 Sun Pharmaceuticals Business Overview
11.11.3 Sun Pharmaceuticals Malignant Mesothelioma Therapeutic Introduction
11.11.4 Sun Pharmaceuticals Revenue in Malignant Mesothelioma Therapeutic Business (2021–2026)
11.11.5 Sun Pharmaceuticals Recent Development
11.12 Eagle Pharmaceuticals
11.12.1 Eagle Pharmaceuticals Company Details
11.12.2 Eagle Pharmaceuticals Business Overview
11.12.3 Eagle Pharmaceuticals Malignant Mesothelioma Therapeutic Introduction
11.12.4 Eagle Pharmaceuticals Revenue in Malignant Mesothelioma Therapeutic Business (2021–2026)
11.12.5 Eagle Pharmaceuticals Recent Development
11.13 Qilu Pharma
11.13.1 Qilu Pharma Company Details
11.13.2 Qilu Pharma Business Overview
11.13.3 Qilu Pharma Malignant Mesothelioma Therapeutic Introduction
11.13.4 Qilu Pharma Revenue in Malignant Mesothelioma Therapeutic Business (2021–2026)
11.13.5 Qilu Pharma Recent Development
11.14 Sichuan Huiyu Pharma
11.14.1 Sichuan Huiyu Pharma Company Details
11.14.2 Sichuan Huiyu Pharma Business Overview
11.14.3 Sichuan Huiyu Pharma Malignant Mesothelioma Therapeutic Introduction
11.14.4 Sichuan Huiyu Pharma Revenue in Malignant Mesothelioma Therapeutic Business (2021–2026)
11.14.5 Sichuan Huiyu Pharma Recent Development
11.15 Nippon Kayaku
11.15.1 Nippon Kayaku Company Details
11.15.2 Nippon Kayaku Business Overview
11.15.3 Nippon Kayaku Malignant Mesothelioma Therapeutic Introduction
11.15.4 Nippon Kayaku Revenue in Malignant Mesothelioma Therapeutic Business (2021–2026)
11.15.5 Nippon Kayaku Recent Development
11.16 Jiangsu Haosen
11.16.1 Jiangsu Haosen Company Details
11.16.2 Jiangsu Haosen Business Overview
11.16.3 Jiangsu Haosen Malignant Mesothelioma Therapeutic Introduction
11.16.4 Jiangsu Haosen Revenue in Malignant Mesothelioma Therapeutic Business (2021–2026)
11.16.5 Jiangsu Haosen Recent Development
11.17 Amgen
11.17.1 Amgen Company Details
11.17.2 Amgen Business Overview
11.17.3 Amgen Malignant Mesothelioma Therapeutic Introduction
11.17.4 Amgen Revenue in Malignant Mesothelioma Therapeutic Business (2021–2026)
11.17.5 Amgen Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Eli Lilly
TEVA
Sanofi
Bristol–Myers Squibb
Pfizer Inc
Roche
Merck
Ono Pharmaceutical
Mylan NV
Fresenius Kabi
Sun Pharmaceuticals
Eagle Pharmaceuticals
Qilu Pharma
Sichuan Huiyu Pharma
Nippon Kayaku
Amgen Inc
Jiangsu Haosen
List of Tables
 Table 1. Global Malignant Mesothelioma Therapeutic Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
 Table 2. Key Players of Pemetrexed
 Table 3. Key Players of Cisplatin
 Table 4. Key Players of Immunotherapy Agents
 Table 5. Key Players of Others
 Table 6. Global Malignant Mesothelioma Therapeutic Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
 Table 7. Global Malignant Mesothelioma Therapeutic Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 8. Global Malignant Mesothelioma Therapeutic Market Size by Region (US$ Million), 2021–2026
 Table 9. Global Malignant Mesothelioma Therapeutic Market Share by Region (2021–2026)
 Table 10. Global Malignant Mesothelioma Therapeutic Forecasted Market Size by Region (US$ Million), 2027–2032
 Table 11. Global Malignant Mesothelioma Therapeutic Market Share by Region (2027–2032)
 Table 12. Malignant Mesothelioma Therapeutic Market Trends
 Table 13. Malignant Mesothelioma Therapeutic Market Drivers
 Table 14. Malignant Mesothelioma Therapeutic Market Challenges
 Table 15. Malignant Mesothelioma Therapeutic Market Restraints
 Table 16. Global Malignant Mesothelioma Therapeutic Revenue by Players (US$ Million), 2021–2026
 Table 17. Global Malignant Mesothelioma Therapeutic Market Share by Players (2021–2026)
 Table 18. Global Top Malignant Mesothelioma Therapeutic Players by Tier (Tier 1, Tier 2, and Tier 3), based on Malignant Mesothelioma Therapeutic Revenue, 2025
 Table 19. Ranking of Global Top Malignant Mesothelioma Therapeutic Companies by Revenue (US$ Million) in 2025
 Table 20. Global 5 Largest Players Market Share by Malignant Mesothelioma Therapeutic Revenue (CR5 and HHI), 2021–2026
 Table 21. Global Key Players of Malignant Mesothelioma Therapeutic, Headquarters and Area Served
 Table 22. Global Key Players of Malignant Mesothelioma Therapeutic, Products and Applications
 Table 23. Global Key Players of Malignant Mesothelioma Therapeutic, Date of General Availability (GA)
 Table 24. Mergers and Acquisitions, Expansion Plans
 Table 25. Global Malignant Mesothelioma Therapeutic Market Size by Type (US$ Million), 2021–2026
 Table 26. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Type (2021–2026)
 Table 27. Global Malignant Mesothelioma Therapeutic Forecasted Market Size by Type (US$ Million), 2027–2032
 Table 28. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Type (2027–2032)
 Table 29. Global Malignant Mesothelioma Therapeutic Market Size by Application (US$ Million), 2021–2026
 Table 30. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Application (2021–2026)
 Table 31. Global Malignant Mesothelioma Therapeutic Forecasted Market Size by Application (US$ Million), 2027–2032
 Table 32. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Application (2027–2032)
 Table 33. North America Malignant Mesothelioma Therapeutic Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 34. North America Malignant Mesothelioma Therapeutic Market Size by Country (US$ Million), 2021–2026
 Table 35. North America Malignant Mesothelioma Therapeutic Market Size by Country (US$ Million), 2027–2032
 Table 36. Europe Malignant Mesothelioma Therapeutic Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 37. Europe Malignant Mesothelioma Therapeutic Market Size by Country (US$ Million), 2021–2026
 Table 38. Europe Malignant Mesothelioma Therapeutic Market Size by Country (US$ Million), 2027–2032
 Table 39. Asia-Pacific Malignant Mesothelioma Therapeutic Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 40. Asia-Pacific Malignant Mesothelioma Therapeutic Market Size by Region (US$ Million), 2021–2026
 Table 41. Asia-Pacific Malignant Mesothelioma Therapeutic Market Size by Region (US$ Million), 2027–2032
 Table 42. Latin America Malignant Mesothelioma Therapeutic Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 43. Latin America Malignant Mesothelioma Therapeutic Market Size by Country (US$ Million), 2021–2026
 Table 44. Latin America Malignant Mesothelioma Therapeutic Market Size by Country (US$ Million), 2027–2032
 Table 45. Middle East & Africa Malignant Mesothelioma Therapeutic Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 46. Middle East & Africa Malignant Mesothelioma Therapeutic Market Size by Country (US$ Million), 2021–2026
 Table 47. Middle East & Africa Malignant Mesothelioma Therapeutic Market Size by Country (US$ Million), 2027–2032
 Table 48. Eli Lilly Company Details
 Table 49. Eli Lilly Business Overview
 Table 50. Eli Lilly Malignant Mesothelioma Therapeutic Product
 Table 51. Eli Lilly Revenue in Malignant Mesothelioma Therapeutic Business (US$ Million), 2021–2026
 Table 52. Eli Lilly Recent Development
 Table 53. Teva Company Details
 Table 54. Teva Business Overview
 Table 55. Teva Malignant Mesothelioma Therapeutic Product
 Table 56. Teva Revenue in Malignant Mesothelioma Therapeutic Business (US$ Million), 2021–2026
 Table 57. Teva Recent Development
 Table 58. Sanofi Company Details
 Table 59. Sanofi Business Overview
 Table 60. Sanofi Malignant Mesothelioma Therapeutic Product
 Table 61. Sanofi Revenue in Malignant Mesothelioma Therapeutic Business (US$ Million), 2021–2026
 Table 62. Sanofi Recent Development
 Table 63. Bristol-Myers Squibb Company Details
 Table 64. Bristol-Myers Squibb Business Overview
 Table 65. Bristol-Myers Squibb Malignant Mesothelioma Therapeutic Product
 Table 66. Bristol-Myers Squibb Revenue in Malignant Mesothelioma Therapeutic Business (US$ Million), 2021–2026
 Table 67. Bristol-Myers Squibb Recent Development
 Table 68. Pfizer Company Details
 Table 69. Pfizer Business Overview
 Table 70. Pfizer Malignant Mesothelioma Therapeutic Product
 Table 71. Pfizer Revenue in Malignant Mesothelioma Therapeutic Business (US$ Million), 2021–2026
 Table 72. Pfizer Recent Development
 Table 73. Roche Company Details
 Table 74. Roche Business Overview
 Table 75. Roche Malignant Mesothelioma Therapeutic Product
 Table 76. Roche Revenue in Malignant Mesothelioma Therapeutic Business (US$ Million), 2021–2026
 Table 77. Roche Recent Development
 Table 78. Merck Company Details
 Table 79. Merck Business Overview
 Table 80. Merck Malignant Mesothelioma Therapeutic Product
 Table 81. Merck Revenue in Malignant Mesothelioma Therapeutic Business (US$ Million), 2021–2026
 Table 82. Merck Recent Development
 Table 83. Ono Pharmaceutical Company Details
 Table 84. Ono Pharmaceutical Business Overview
 Table 85. Ono Pharmaceutical Malignant Mesothelioma Therapeutic Product
 Table 86. Ono Pharmaceutical Revenue in Malignant Mesothelioma Therapeutic Business (US$ Million), 2021–2026
 Table 87. Ono Pharmaceutical Recent Development
 Table 88. Mylan Company Details
 Table 89. Mylan Business Overview
 Table 90. Mylan Malignant Mesothelioma Therapeutic Product
 Table 91. Mylan Revenue in Malignant Mesothelioma Therapeutic Business (US$ Million), 2021–2026
 Table 92. Mylan Recent Development
 Table 93. Fresenius Kabi Company Details
 Table 94. Fresenius Kabi Business Overview
 Table 95. Fresenius Kabi Malignant Mesothelioma Therapeutic Product
 Table 96. Fresenius Kabi Revenue in Malignant Mesothelioma Therapeutic Business (US$ Million), 2021–2026
 Table 97. Fresenius Kabi Recent Development
 Table 98. Sun Pharmaceuticals Company Details
 Table 99. Sun Pharmaceuticals Business Overview
 Table 100. Sun Pharmaceuticals Malignant Mesothelioma Therapeutic Product
 Table 101. Sun Pharmaceuticals Revenue in Malignant Mesothelioma Therapeutic Business (US$ Million), 2021–2026
 Table 102. Sun Pharmaceuticals Recent Development
 Table 103. Eagle Pharmaceuticals Company Details
 Table 104. Eagle Pharmaceuticals Business Overview
 Table 105. Eagle Pharmaceuticals Malignant Mesothelioma Therapeutic Product
 Table 106. Eagle Pharmaceuticals Revenue in Malignant Mesothelioma Therapeutic Business (US$ Million), 2021–2026
 Table 107. Eagle Pharmaceuticals Recent Development
 Table 108. Qilu Pharma Company Details
 Table 109. Qilu Pharma Business Overview
 Table 110. Qilu Pharma Malignant Mesothelioma Therapeutic Product
 Table 111. Qilu Pharma Revenue in Malignant Mesothelioma Therapeutic Business (US$ Million), 2021–2026
 Table 112. Qilu Pharma Recent Development
 Table 113. Sichuan Huiyu Pharma Company Details
 Table 114. Sichuan Huiyu Pharma Business Overview
 Table 115. Sichuan Huiyu Pharma Malignant Mesothelioma Therapeutic Product
 Table 116. Sichuan Huiyu Pharma Revenue in Malignant Mesothelioma Therapeutic Business (US$ Million), 2021–2026
 Table 117. Sichuan Huiyu Pharma Recent Development
 Table 118. Nippon Kayaku Company Details
 Table 119. Nippon Kayaku Business Overview
 Table 120. Nippon Kayaku Malignant Mesothelioma Therapeutic Product
 Table 121. Nippon Kayaku Revenue in Malignant Mesothelioma Therapeutic Business (US$ Million), 2021–2026
 Table 122. Nippon Kayaku Recent Development
 Table 123. Jiangsu Haosen Company Details
 Table 124. Jiangsu Haosen Business Overview
 Table 125. Jiangsu Haosen Malignant Mesothelioma Therapeutic Product
 Table 126. Jiangsu Haosen Revenue in Malignant Mesothelioma Therapeutic Business (US$ Million), 2021–2026
 Table 127. Jiangsu Haosen Recent Development
 Table 128. Amgen Company Details
 Table 129. Amgen Business Overview
 Table 130. Amgen Malignant Mesothelioma Therapeutic Product
 Table 131. Amgen Revenue in Malignant Mesothelioma Therapeutic Business (US$ Million), 2021–2026
 Table 132. Amgen Recent Development
 Table 133. Research Programs/Design for This Report
 Table 134. Key Data Information from Secondary Sources
 Table 135. Key Data Information from Primary Sources
 Table 136. Authors List of This Report


List of Figures
 Figure 1. Malignant Mesothelioma Therapeutic Picture
 Figure 2. Global Malignant Mesothelioma Therapeutic Market Size Comparison by Type (US$ Million), 2021–2032
 Figure 3. Global Malignant Mesothelioma Therapeutic Market Share by Type: 2025 vs 2032
 Figure 4. Pemetrexed Features
 Figure 5. Cisplatin Features
 Figure 6. Immunotherapy Agents Features
 Figure 7. Others Features
 Figure 8. Global Malignant Mesothelioma Therapeutic Market Size by Application (US$ Million), 2021–2032
 Figure 9. Global Malignant Mesothelioma Therapeutic Market Share by Application: 2025 vs 2032
 Figure 10. Pleural Mesothelioma Case Studies
 Figure 11. Peritoneal Mesothelioma Case Studies
 Figure 12. Others Case Studies
 Figure 13. Malignant Mesothelioma Therapeutic Report Years Considered
 Figure 14. Global Malignant Mesothelioma Therapeutic Market Size (US$ Million), Year-over-Year: 2021–2032
 Figure 15. Global Malignant Mesothelioma Therapeutic Market Size, (US$ Million), 2021 vs 2025 vs 2032
 Figure 16. Global Malignant Mesothelioma Therapeutic Market Share by Region: 2025 vs 2032
 Figure 17. Global Malignant Mesothelioma Therapeutic Market Share by Players in 2025
 Figure 18. Global Malignant Mesothelioma Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
 Figure 19. The Top 10 and 5 Players Market Share by Malignant Mesothelioma Therapeutic Revenue in 2025
 Figure 20. North America Malignant Mesothelioma Therapeutic Market Size YoY Growth (US$ Million), 2021–2032
 Figure 21. North America Malignant Mesothelioma Therapeutic Market Share by Country (2021–2032)
 Figure 22. United States Malignant Mesothelioma Therapeutic Market Size YoY Growth (US$ Million), 2021–2032
 Figure 23. Canada Malignant Mesothelioma Therapeutic Market Size YoY Growth (US$ Million), 2021–2032
 Figure 24. Europe Malignant Mesothelioma Therapeutic Market Size YoY Growth (US$ Million), 2021–2032
 Figure 25. Europe Malignant Mesothelioma Therapeutic Market Share by Country (2021–2032)
 Figure 26. Germany Malignant Mesothelioma Therapeutic Market Size YoY Growth (US$ Million), 2021–2032
 Figure 27. France Malignant Mesothelioma Therapeutic Market Size YoY Growth (US$ Million), 2021–2032
 Figure 28. U.K. Malignant Mesothelioma Therapeutic Market Size YoY Growth (US$ Million), 2021–2032
 Figure 29. Italy Malignant Mesothelioma Therapeutic Market Size YoY Growth (US$ Million), 2021–2032
 Figure 30. Russia Malignant Mesothelioma Therapeutic Market Size YoY Growth (US$ Million), 2021–2032
 Figure 31. Ireland Malignant Mesothelioma Therapeutic Market Size YoY Growth (US$ Million), 2021–2032
 Figure 32. Asia-Pacific Malignant Mesothelioma Therapeutic Market Size YoY Growth (US$ Million), 2021–2032
 Figure 33. Asia-Pacific Malignant Mesothelioma Therapeutic Market Share by Region (2021–2032)
 Figure 34. China Malignant Mesothelioma Therapeutic Market Size YoY Growth (US$ Million), 2021–2032
 Figure 35. Japan Malignant Mesothelioma Therapeutic Market Size YoY Growth (US$ Million), 2021–2032
 Figure 36. South Korea Malignant Mesothelioma Therapeutic Market Size YoY Growth (US$ Million), 2021–2032
 Figure 37. Southeast Asia Malignant Mesothelioma Therapeutic Market Size YoY Growth (US$ Million), 2021–2032
 Figure 38. India Malignant Mesothelioma Therapeutic Market Size YoY Growth (US$ Million), 2021–2032
 Figure 39. Australia & New Zealand Malignant Mesothelioma Therapeutic Market Size YoY Growth (US$ Million), 2021–2032
 Figure 40. Latin America Malignant Mesothelioma Therapeutic Market Size YoY Growth (US$ Million), 2021–2032
 Figure 41. Latin America Malignant Mesothelioma Therapeutic Market Share by Country (2021–2032)
 Figure 42. Mexico Malignant Mesothelioma Therapeutic Market Size YoY Growth (US$ Million), 2021–2032
 Figure 43. Brazil Malignant Mesothelioma Therapeutic Market Size YoY Growth (US$ Million), 2021–2032
 Figure 44. Middle East & Africa Malignant Mesothelioma Therapeutic Market Size YoY Growth (US$ Million), 2021–2032
 Figure 45. Middle East & Africa Malignant Mesothelioma Therapeutic Market Share by Country (2021–2032)
 Figure 46. Israel Malignant Mesothelioma Therapeutic Market Size YoY Growth (US$ Million), 2021–2032
 Figure 47. Saudi Arabia Malignant Mesothelioma Therapeutic Market Size YoY Growth (US$ Million), 2021–2032
 Figure 48. UAE Malignant Mesothelioma Therapeutic Market Size YoY Growth (US$ Million), 2021–2032
 Figure 49. Eli Lilly Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2021–2026)
 Figure 50. Teva Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2021–2026)
 Figure 51. Sanofi Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2021–2026)
 Figure 52. Bristol-Myers Squibb Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2021–2026)
 Figure 53. Pfizer Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2021–2026)
 Figure 54. Roche Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2021–2026)
 Figure 55. Merck Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2021–2026)
 Figure 56. Ono Pharmaceutical Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2021–2026)
 Figure 57. Mylan Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2021–2026)
 Figure 58. Fresenius Kabi Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2021–2026)
 Figure 59. Sun Pharmaceuticals Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2021–2026)
 Figure 60. Eagle Pharmaceuticals Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2021–2026)
 Figure 61. Qilu Pharma Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2021–2026)
 Figure 62. Sichuan Huiyu Pharma Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2021–2026)
 Figure 63. Nippon Kayaku Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2021–2026)
 Figure 64. Jiangsu Haosen Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2021–2026)
 Figure 65. Amgen Revenue Growth Rate in Malignant Mesothelioma Therapeutic Business (2021–2026)
 Figure 66. Bottom-up and Top-down Approaches for This Report
 Figure 67. Data Triangulation
 Figure 68. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS

Global Malignant Pleural Mesothelioma Treatment Market Insights Forecast to 2030
Global Uterine Sarcoma Treatment Market Insights Forecast to 2030
Global Rectal Cancer Therapeutics Market Insights Forecast to 2030
Global Malignant Ascites Treatment Market Insights Forecast to 2030
Global Adult Malignant Glioma Therapeutics Market Insights Forecast to 2030
Global Malignant Glioma Therapeutics Market Research Report 2024
Global Uterine Cancer Therapies and Diagnostic Market Insights Forecast to 2030
Global Asbestosis Treatment Drugs Market Research Report 2025
Global Solid Tumor Cancer Treatment Market Insights Forecast to 2030
Global Cell Separation and Characterization in Solid Tumors Market Insights Forecast to 2030
Global Fallopian Tube Cancer Therapeutics Market Insights Forecast to 2030
Global Ovarian Cancer Market Research Report 2024
Global Drugs for Oncology Market Insights Forecast to 2030
Hematologic Malignancies Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Prostate Cancer Market Insights Forecast to 2030
Global Oncology Drugs Market Insights Forecast to 2030
Global Solid Tumor Therapeutics Market Research Report 2024
Global Oncology Therapeutic Drug Market Research Report 2024
Adult Malignant Glioma Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Metastatic Bones Cancer Market Insights Forecast to 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions